Biotechnology - Waltham, Massachusetts, United States
X-Rx is an early stage biotech company focused on the development of small molecule medicines in inflammation, fibrosis and oncology. Our portfolio includes our lead program X-165, a novel autotaxin inhibitor, being developed for multiple indications in fibrosis and targets across a number of families with multiple series of chemical starting points.